Navigation Links
Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy

r /> and female patients aged 18 to 65 and suffering from mild to moderate perennial allergic rhinitis due
to house dust mite allergy. Upon entry into the study, the allergic status of the individual
participants was recorded by the conjunctival provocation test, a commonly used allergy test. The
study participants were randomized into 4 treatment groups with 10 patients each and received 6
weekly subcutaneous injections of either i) 300 ?g CYT003-QbG10 alone, ii) 300 ?g CYT003-QbG10
plus a low dose of house dust mite allergen extract (designated CYT005-AllQbG10), iii) a low dose of
house dust mite allergen extract alone, or iv) placebo. The house dust mite allergen dose
administered in treatment arms ii) and iii) was 10-times lower than that usually applied in
conventional desensitization therapy. Two weeks after the last dose, the allergic status of the
patients was again assessed by the conjunctival provocation test, which served as the primary
efficacy parameter of the study. All 40 patients were included into the analysis.

About CYT003-QbG10
CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma
and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like
particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is
designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response
in order to suppress an “allergic” Th2 type immune response. An earlier, open-label phase IIa study
with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose
showed excellent long-term efficacy in patients allergic to dust mites. Furthermore, a placebocontrolled
phase IIa study with CYT003-QbG10 showed significant improvement of allergy symptoms
in hay fever patients. CYT003-Qb
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014  Decision ... launched anti-vascular endothelial growth factor (VEGF) agent for wet ... and Medicare Advantage plans as Genentech,s Lucentis, which is ... although surveyed managed care organization (MCO) directors do not ... Eylea is slightly more likely than Lucentis to be ...
(Date:9/18/2014)... Pa. , Sept. 18, 2014 /PRNewswire/ ... solutions, was recognized as the Disruptive Innovator ... its ePharmaONE cloud-based eClinical platform. This solution ... electronic trial master file (eTMF), a remote ... and ePharmaSolutions, ReferralPlus+ patient screening and matching ...
(Date:9/18/2014)... Sept. 18, 2014  A $3 million grant from ... University of Michigan to establish a national center of ... Center for Aging Research at U-M will focus on ... slow the effects of aging and postpone diseases in ... that can help develop medications that may help people ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
... bolstering current systems for assessing and monitoring drug safety, researchers ... combines multiple forms of widely available data to predict adverse ... of drug safety issues as they accumulate over time in ... issues years in advance. This study, led by ...
... Food and Drug Administration is warning consumers again not to ... and sold by various companies, due to serious potential health ... Massager is a personal massage device sold in retail ... provide users with a deep tissue massage to the neck, ...
Cached Medicine Technology:Taking a Predictive Approach to Identifying Adverse Drug Reactions 2Taking a Predictive Approach to Identifying Adverse Drug Reactions 3FDA: Do Not Use ShoulderFlex Massagers 2FDA: Do Not Use ShoulderFlex Massagers 3
(Date:9/18/2014)... 2014 (HealthDay News) -- Older people become more physically ... the balance of stress hormones during bereavement changes with ... who are grieving are more likely to have weakened ... "During the difficult weeks and months after loss, we ... most abundant type of white blood cell and as ...
(Date:9/18/2014)... San Luis Obispo, CA (PRWEB) September 18, 2014 ... Bunion Bootie introduced their newest, patent pending bunion splint ... , As one loyalist, Rosa, wrote: "I was absolutely delighted. ... comfortable... I honestly forget I am wearing them. THANK YOU ... the recently introduced design by saying, "The hole used to ...
(Date:9/18/2014)... Mozes HealthDay Reporter , THURSDAY, ... emergency room waiting times, patients seeking care at larger urban ... clock than those seen at smaller or more rural facilities, ... ability to provide timely emergency care varies dramatically across hospitals ... the new research, Dr. Renee Hsia, an associate professor at ...
(Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
(Date:9/18/2014)... Seattle, WA (PRWEB) September 18, 2014 ... management organizations, has published a white paper, “Advancing ... Optimization of Health Information Technology.” , Authors Jeff ... PCMH CCE provide guidance to organizations engaged in the ... showing how health IT can bolster PCMH objectives, such ...
Breaking Medicine News(10 mins):Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... recipient,s tissue, study finds, , SUNDAY, Nov. 22 (HealthDay ... -- a missing gene -- boosts the risk that ... complication called graft-versus-host disease. , The immune system-related ... variation and the donor does not. , When ...
... ... can be both fun and joyous. It can also be stressful and tiring ... foods -- factors that can, over time, increase your risk of cancer. That,s ... 10 Food Tips that can help ensure a happier, more healthful holiday season, ...
... WASHINGTON, Nov. 21 Tonight, in a partisan vote, the ... the government takeover of health care. Among the several objectionable ... and individual mandates, is the government funding for elective abortion, ... bill provides subsidies for private plans that cover elective abortion. ...
... Nov. 21 Milvia Lopez, by her attorney MICHAEL STEWART ... Court, New York County, bearing Index # 112888/2009. The complaint ... ("TEE") at ST. VINCENT,S HOSPITAL , doctors used an ... The complaint alleges that several hours after being discharged from ...
... , LONDON, November 21, 2009 Test Test Test ... Test Test,Test Test Test Test Test Test Test Test Test Test Test Test ... Test , More test More test More test More ... test More test More test More test More,test More test , , ...
... ... available on the iPhone and iPod Touch. , ... Mountain View, CA (PRWEB) November 21, 2009 -- HAPPYneuron,s most popular and ... designed to help banish that ,tip of the tongue, syndrome forever. , , ,The SplitWords ...
Cached Medicine News:Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 3Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3
... 4, 8, or 12 channel pipettors. Angled sides ... of the solution. Corners have pouring lips to ... polystyrene containing no regrinds. Sterile 5/bag packaging for ... mm W x 152 mm L x 35 ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
... Gilsons Pipette Aid, which is for use ... rapidly, and comfortably with precision. It works with ... the volume range from 1 mL to 100 ... valve and replaceable membrane filters, which protect the ...
Inquire...
Medicine Products: